Barclay A Phillips - Net Worth and Insider Trading
Barclay A Phillips Net Worth
The estimated net worth of Barclay A Phillips is at least $11,501 dollars as of 2025-05-08. Barclay A Phillips is the SVP, CFO of Novavax Inc and owns about 1,933 shares of Novavax Inc (NVAX) stock worth over $11,501. Barclay A Phillips is also the SVP & CFO of G1 Therapeutics Inc and owns about 0 shares of G1 Therapeutics Inc (GTHX) stock worth over $0. Details can be seen in Barclay A Phillips's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Barclay A Phillips has not made any transactions after 2018-11-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Barclay A Phillips
Barclay A Phillips Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Barclay A Phillips owns 4 companies in total, including Immunic Inc (IMUX) , G1 Therapeutics Inc (GTHX) , and Novavax Inc (NVAX) among others .
Click here to see the complete history of Barclay A Phillips’s form 4 insider trades.
Insider Ownership Summary of Barclay A Phillips
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| IMUX | Immunic Inc | 2019-11-18 | director |
| GTHX | G1 Therapeutics Inc | 2018-11-15 | SVP & Chief Financial Officer |
| NVAX | Novavax Inc | 2017-07-31 | director |
 | | 2006-02-09 | director |
Barclay A Phillips Latest Holdings Summary
Barclay A Phillips currently owns a total of 2 stocks. Among these stocks, Barclay A Phillips owns 1,933 shares of Novavax Inc (NVAX) as of July 31, 2017, with a value of $11,501 and a weighting of 100%. Barclay A Phillips also owns 0 shares of G1 Therapeutics Inc (GTHX) as of November 15, 2018, with a value of $0 and a weighting of 0%.
Latest Holdings of Barclay A Phillips
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NVAX | Novavax Inc | 2017-07-31 | 1,933 | 5.95 | 11,501 |
| GTHX | G1 Therapeutics Inc | 2018-11-15 | 0 | 7.15 | 0 |
Holding Weightings of Barclay A Phillips
Barclay A Phillips Form 4 Trading Tracker
According to the SEC Form 4 filings, Barclay A Phillips has made a total of 0 transactions in Novavax Inc (NVAX) over the past 5 years. The most-recent trade in Novavax Inc is the acquisition of 103 shares on July 31, 2017, which cost Barclay A Phillips around $1,831.
According to the SEC Form 4 filings, Barclay A Phillips has made a total of 0 transactions in G1 Therapeutics Inc (GTHX) over the past 5 years. The most-recent trade in G1 Therapeutics Inc is the sale of 5,000 shares on November 15, 2018, which brought Barclay A Phillips around $199,600.
Insider Trading History of Barclay A Phillips
- 1
Barclay A Phillips Trading Performance
GuruFocus tracks the stock performance after each of Barclay A Phillips's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Barclay A Phillips is -1.46%. GuruFocus also compares Barclay A Phillips's trading performance to market benchmark return within the same time period. The performance of stocks bought by Barclay A Phillips within 3 months outperforms 6 times out of 11 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Barclay A Phillips's insider trading performs compared to the benchmark.
Performance of Barclay A Phillips
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.44 | | | | | |
| Relative Return to S&P 500(%) | 5.98 | | | | | |
Barclay A Phillips Ownership Network
Ownership Network List of Barclay A Phillips
Ownership Network Relation of Barclay A Phillips
Barclay A Phillips Owned Company Details
What does Immunic Inc do?
Who are the key executives at Immunic Inc?
Barclay A Phillips is the director of Immunic Inc. Other key executives at Immunic Inc include director & CEO & President Daniel Vitt , PAO and Controller Glenn Whaley , and Chief Medical Officer Andreas Muehler .
Immunic Inc (IMUX) Insider Trades Summary
Over the past 18 months, Barclay A Phillips made no insider transaction in Immunic Inc (IMUX). Other recent insider transactions involving Immunic Inc (IMUX) include a net purchase of 87,300 shares made by Richard Alan Rudick , and a net purchase of 14,000 shares made by Daniel Vitt .
In summary, during the past 3 months, insiders sold 0 shares of Immunic Inc (IMUX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunic Inc (IMUX) were sold and 101,300 shares were bought by its insiders, resulting in a net purchase of 101,300 shares.
Immunic Inc (IMUX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Immunic Inc Insider Transactions
Barclay A Phillips Mailing Address
Above is the net worth, insider trading, and ownership report for Barclay A Phillips. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Barclay A Phillips's mailing address is: Carlsbad Ca 92008.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
